North America Epigenetics Market

The North America epigenetics market is expected to reach USD 1.78 billion by 2030 from USD 0.93 billion in 2025, at a CAGR of 13.8% during the forecast period. Major factors supporting growth in the North America epigenetics market include robust research funding and healthcare infrastructure, substantial investment in epigenetic research, and a high prevalence of cancer and other chronic diseases.

The North America epigenetics market is competitive. Prominent players in the North America epigenetics market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher (US), Bio-Rad Laboratories, Inc. (US), and Active Motif (US), among others.

To know about the assumptions considered for the study download the pdf brochure

In July 2024, Thermo Fisher Scientific Inc. acquired Olink, a leading provider of next-generation proteomics solutions. This acquisition strengthens the life science segment of Thermo Fisher Scientific.
               
Thermo Fisher Scientific Inc. is a leading company in the North American epigenetics market, supported by its broad portfolio of sample preparation, nucleic acid purification, qPCR, and NGS-enabling reagents that feed directly into methylation and chromatin workflows. The company has strong penetration across academic labs, biopharma R&D, and CROs, where recurring consumables drive repeat purchases. Thermo also drives adoption through integrated workflows that simplify “sample-to-answer” execution and improve consistency across sites. This combination of installed base, workflow breadth, and dependable supply chain keeps Thermo well-positioned across North America’s research and translational epigenomics demand.

Illumina, Inc. is a leading player in North American epigenetics, anchored by its dominant sequencing ecosystem and the widespread use of methylation sequencing and epigenome-wide profiling in large research programs. Its strong installed base in genomics centers and biopharma labs enables high-throughput epigenetic analysis, while compatible informatics tools support scalable data processing and interpretation. Illumina’s platforms often serve as the backbone for population-scale and consortium-led studies where standardization and throughput are critical. This leadership in sequencing infrastructure and data workflows sustains Illumina’s prominence in the region.

Merck KGaA Merck holds a strong position in North American epigenetics market through a deep portfolio of epigenetics reagents, high-quality antibodies, and chromatin-focused kits used across ChIP and related applications. The company’s strength lies in enabling reliable upstream experimental performance, where reagent quality and lot-to-lot consistency directly impact reproducibility. Merck also supports broader adoption through established distribution, technical support, and a wide consumables footprint across life science research labs. These recurring consumables demand and strong brand trust reinforce Merck’s relevance across North America’s epigenetics workflows.

Market Ranking

The North America epigenetics market is competitive, with leading suppliers gaining share through broad workflow coverage, strong installed bases, and reliable supply. Thermo Fisher Scientific is a key leader, offering end-to-end consumables for methylation and chromatin workflows, including sample and library preparation. Illumina remains dominant through its sequencing platforms that enable large-scale epigenome profiling. Merck is well positioned with high-performing antibodies and epigenetics reagents for chromatin biology, while Bio-Rad is gaining traction in ddPCR-based methylation quantification and biomarker validation. Buying decisions increasingly prioritize standardized, reproducible workflows and strong documentation, supporting recurring consumables demand.

Related Reports:

North America Epigenetics Market by Product & Service [Enzymes, Kits & Reagents (Antibodies), Software], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology]-Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com